Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Campylobacter jejuni component of Activax oral multivalent vaccine: ANX completed dosing of 33 subjects in its U.S. double-blind trial of 3 adjuvant doses with

Antex Biologics Inc. (ANX), Gaithersburg, Md.
Product: Campylobacter jejuni component of Activax

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE